Project Details
| Status | Active |
|---|---|
| Effective start/end date | 02/5/24 → 12/7/27 |
Funding
- Amgen Incorporated: $25,830.00
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression...
- Wang, Zhen (PI)
Project: Research